Clinical trial
Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent…
NCT00370396 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00370396 |
|---|---|
| Title | Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine. |
| Official title | To Assess the Safety, Reactogenicity & Immunogenicity of a 4th Dose of GSK Biologicals' Pneumococcal Vaccine or Prevenar™ in Children (12-18 Months) Previously Vaccinated in the Primary Study NCT00307554 With Either Pneumococcal Vaccine or Prevenar™ |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Streptococcal |
| Intervention type | Biological |
| Interventions | Synflorix, Prevenar, Infanrix hexa |
| Enrollment | 1,200 |
| Start date | Sep 25, 2006 |
| Primary completion | Jun 4, 2007 |
| Completion | Nov 6, 2007 |
| First posted | Aug 31, 2006 |
| Last update posted | Jun 10, 2019 |
| Countries | Finland, France, Poland |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: